Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus

Bone Reports

Qiuhu Shi¹  Anjali Sharma²  Audrey L. French³  Ryan D. Ross⁴  Michael T. Yin⁵  Lena Al-Harthi⁶  Phyllis C. Tien⁷  Kathleen M. Weber⁸  Donald R. Hoover⁹ 

[1] Corresponding author.;Molecular Medicine, Rush University Medical Center, Chicago, IL, United States of America;Cook County Health/CORE Center and Hektoen Institute of Medicine, Chicago, IL, United States of America;;Department of Cell &Department of Medicine, Stroger Hospital of Cook County/CORE Center, Rush University, Chicago, IL, United States of America;Department of Medicine, University of California, San Francisco and Medical Service, Department of Veteran Affairs Medical Center, San Francisco, CA, United States of America;Department of Statistics and Institute for Health Health Care Policy and Aging Research Rutgers University, Piscataway, NJ, United States of America;New York Medical College, Valhalla, NY, United States of America;State University of New York, Downstate, Brooklyn, NY, United States of America;

关键词: Bone;    Bone mineral density;    HIV;    Sclerostin;    Antiretroviral therapy;    Tenofovir;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: Low bone mineral density (BMD) is commonly observed in people living with HIV (PLWH), however the cause for this BMD loss remains unclear. Sclerostin, a bone-derived antagonist to the Wnt/β-catenin-pathway, suppresses bone remodeling and is positively associated with BMD. The goal of the current study was to investigate associations between sclerostin and BMD in a cohort of HIV-seropositive and demographically-matched seronegative women. Methods: This cross-sectional analysis used a subset of early postmenopausal women enrolled in the Women's Interagency HIV Study (WIHS). BMD was assessed at the lumbar spine, total hip, femoral neck, and distal and ultradistal radius via dual energy x-ray absorptiometry (DXA). Circulating sclerostin was assessed via commercial ELISAs. Univariate and multivariate linear regression modeling tested associations between sclerostin and BMD after adjusting for a variety of BMD-modifying variables. Results: HIV-seropositive women had significantly reduced BMD at all skeletal sites compared to HIV-seronegative women. There was no difference in sclerostin levels according to HIV-serostatus (0.25 vs 0.27 ng/mL in HIV-seronegative and HIV-seropositive, respectively, p = 0.71). Circulating sclerostin was positively associated with BMD at all sites in both univariate and multivariate models adjusting for HIV status, age, BMI, and race, although the coefficients of association were attenuated in HIV-seropositive women. The positive association between sclerostin and BMD among seropositive women remained statistically significant after adjusting for ART or tenofovir disoproxil fumarate (TDF) use. Conclusions: The current study suggests that circulating sclerostin is a biomarker for bone mass for both HIV seronegative and seropositive women using and not using ART. The lower coefficients of association between sclerostin and BMD by HIV status may suggest HIV-induced alternation in osteocyte function.

【 授权许可】

Unknown